Contour Variability in Thyroid Eye Disease with Compressive Optic Neuropathy Treated with Radiation Therapy.


Journal

Advances in radiation oncology
ISSN: 2452-1094
Titre abrégé: Adv Radiat Oncol
Pays: United States
ID NLM: 101677247

Informations de publication

Date de publication:
Historique:
received: 24 10 2019
accepted: 11 02 2020
entrez: 22 10 2020
pubmed: 23 10 2020
medline: 23 10 2020
Statut: epublish

Résumé

Few studies have evaluated the methodology by which radiation therapy (RT) for thyroid eye disease and compressive optic neuropathy is performed. The objective of this study was to retrospectively review our experience from a radiation planning standpoint and to determine whether current treatment methods provide adequate dose to target and collateral structures. A retrospective review of 52 patients (104 orbits) with bilateral thyroid eye disease and compressive optic neuropathy treated with RT (20 Gy in 10 fractions) at our institution. RT plans were analyzed for target volumes and doses. Visual fields, color plates, and visual acuity were assessed pretreatment and at last available follow-up post RT. A standardized, anatomic contour of the retro-orbital space was applied to these retrospective plans to determine dose to the entire space, rather than the self-selected target structure. Compared with the anatomic retro-orbital space, the original contour overlapped by only 68%. Maximum and mean dose was 2134 cGy and 1910 cGy to the anatomic retro-orbital space. Consequently, 39.8% of the orbits had a mean dose <19 Gy (<17 Gy 16.4%, <18 Gy 27.6% <19 Gy 37.8%, <20 Gy 59.2%, 20-21 Gy 35.8%, >21 Gy 5%). There was no significant association of improvement in color plates ( Without a standardized protocol for contouring in thyroid eye disease, target delineation was found to be rather varied, even among the same practitioner. Differences in dose to the anatomic retro-orbital space did not affect outcomes in the follow-up period. Although precise contouring of the retro-orbital space may be of little clinical consequence overall, a >0.5 cm space from the lens may significantly reduce or delay cataractogenesis.

Identifiants

pubmed: 33089016
doi: 10.1016/j.adro.2020.02.005
pii: S2452-1094(20)30028-2
pmc: PMC7560569
doi:

Types de publication

Journal Article

Langues

eng

Pagination

804-808

Informations de copyright

© 2020 The Authors.

Références

Ophthalmology. 1988 Nov;95(11):1515-21
pubmed: 3211460
Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):944-51
pubmed: 19215827
Ophthalmic Plast Reconstr Surg. 2013 Nov-Dec;29(6):431-6
pubmed: 24217474
Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):857-64
pubmed: 11020584
Orbit. 2017 Aug;36(4):201-207
pubmed: 28453366
Graefes Arch Clin Exp Ophthalmol. 2010 Jan;248(1):103-9
pubmed: 19865824
Curr Opin Ophthalmol. 2012 Sep;23(5):427-32
pubmed: 22729183
Am J Ophthalmol. 2014 Jun;157(6):1299-305
pubmed: 24582992
Ophthalmology. 2001 Sep;108(9):1523-34
pubmed: 11535445
Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):650-9
pubmed: 21281895
Semin Radiat Oncol. 2005 Jul;15(3):136-45
pubmed: 15983939
Am J Ophthalmol Case Rep. 2016 Jun 29;3:50-53
pubmed: 29503909
Clin Exp Ophthalmol. 2017 Aug;45(6):592-597
pubmed: 28181362
J Clin Endocrinol Metab. 1973 Aug;37(2):276-85
pubmed: 4198257
Ophthalmology. 1991 Sep;98(9):1443-8
pubmed: 1945322
J Endocrinol Invest. 1990 Apr;13(4):287-92
pubmed: 2370423
Ophthalmic Plast Reconstr Surg. 2015 Nov-Dec;31(6):445-8
pubmed: 25621464
J Med Phys. 2008 Oct;33(4):136-40
pubmed: 19893706
Surv Ophthalmol. 2009 Sep-Oct;54(5):545-68
pubmed: 19682622
Radiat Oncol. 2010 Mar 15;5:21
pubmed: 20230613
Lancet. 1993 Oct 16;342(8877):949-54
pubmed: 8105213
Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):182-9
pubmed: 12504052
Am J Ophthalmol. 1991 Nov 15;112(5):600-1
pubmed: 1951605
J Clin Endocrinol Metab. 2000 Jan;85(1):102-8
pubmed: 10634372
Ophthalmic Plast Reconstr Surg. 2018 Mar/Apr;34(2):172-177
pubmed: 29517594
Hong Kong Med J. 2005 Oct;11(5):322-30
pubmed: 16219950
Ophthalmic Plast Reconstr Surg. 2002 May;18(3):177-82
pubmed: 12021647
Ophthalmic Plast Reconstr Surg. 2018 Jul/Aug;34(4S Suppl 1):S98-S104
pubmed: 29771752
Trans Am Ophthalmol Soc. 1994;92:477-588
pubmed: 7886878
Lancet. 1989 Sep 16;2(8664):690-1
pubmed: 2570949
Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):372-6
pubmed: 16965989

Auteurs

Tavish Nanda (T)

Columbia University Irving Medical Center Harkness Eye Institute, New York, New York.

Andrew Sanchez (A)

Columbia University College of Physicians and Surgeons, New York, New York.

Juhi Purswani (J)

Department of Radiation Oncology, New York University, New York, New York.

Cheng-Chia Wu (CC)

Department of Radiation Oncology, Columbia University Medical Center, New York, New York.

Michael Kazim (M)

Columbia University Irving Medical Center Harkness Eye Institute, New York, New York.
Department of Surgery, Columbia University Irving Medical Center, New York, New York.

Tony J C Wang (TJC)

Department of Radiation Oncology, Columbia University Medical Center, New York, New York.

Classifications MeSH